

Early "Fast Track"

Modern technology may well be a driving force behind the current trend to rapid publication of scientific papers, as Leslie Roberts describes in her News & Comment article (18 Jan., p. 260). Yet more than three centuries ago, when the scientific journal was a new invention, mail was carried by horse, and printing was done by hand, it was possible to publish a scientific paper in a few weeks.

Isaac Newton's discovery of the compound nature of sunlight, published in *Philosophical Transactions*, no. 80 (19 February 1672), was the first major scientific discovery to be announced in a journal rather than a book (1). Just 7 years earlier, Henry Oldenburg (the "obscure secretary of the Royal Society of London" mentioned by Roberts) had founded *Philosophical Transactions*, the first periodical devoted solely to scientific matters. Newton's paper was dated "Cambridge/ Feb: 6th" and was received by Oldenburg in London on 8 February. The paper was therefore published in a near record 11 days after receipt. If in a skeptical spirit we choose to doubt that that issue actually appeared on its publication date, the paper was still published—at the outmost—in an impressive 32 days, for on 11 March, Oldenburg sent a copy of that issue to Christiaan Huygens in Paris.

The "fast track" also appears to have been established at this time. Although Newton was a young, unpublished professor, he was a rising star of English science. Shortly before Christmas 1671, his reflecting telescope (the first ever constructed) was greeted with great acclaim by the Royal Society, and Newton was immediately elected a Fellow. On 18 January, Newton advised Oldenburg that he was preparing another contribution that he considered "the oddest if not the most considerable detection which hath hitherto been made in the operation of Nature" (1, pp. 82–83). The week before the paper arrived, he promised Oldenburg he would soon dispatch his paper.

The refereeing process, however, was rather different then. The negative report of Robert Hooke, at the time England's leading authority on optics, neither halted nor even delayed publication. After Hooke delivered his critical report to the Society on 15 February, it nonetheless decided that "the printing of Mr. Newton's discourse . . . might go on" (1, p. 115). The matter did not end there, for the two carried out a

notorious, rancorous dispute over the course of many years.

ALAN E. SHAPIRO
Program in History of Science
and Technology,
University of Minnesota,
Minneapolis, MN 55455

NOTES

1. The chronology recounted here may be readily established from *The Correspondence of Isaac Newton*, Vol. 1, 1661–1675 [H. W. Turnbull, Ed. (Cambridge Univ. Press, New York, 1959)].

Drug Abuse Policy

A. Goldstein and H. Kalant ("Drug policy: Striking the right balance," 28 Sept., p. 1513) discuss the ethical options facing policy-makers and argue for reducing both the supply and demand of illegal drugs. However, abuse of legal, prescription drugs accounts for the majority of drug-related emergency room visits, 70% of all drug-related deaths, and more injuries and deaths than all illegal drugs combined (1). More than 300 million doses of drugs that are regulated by the Controlled Substances Act are abused each year, 80 to 90% of which are obtained from physicians, pharmacies, and hospitals (2).

Efforts to control prescription drug abuse have received neither the attention nor the funds that illegal drug programs have. Individual states have successfully employed triple prescription programs (3) or developed new techniques for data analysis (4) to reduce the availability of prescription drugs, but there is little federal emphasis in this area. Some 0.3 to 0.4% of physicians over-prescribe drugs with abuse potential (4), as can be identified by records of the Drug Enforcement Administration, prescription audits, Medicaid audits, and triple prescription programs. Because prescription drugs represent the majority of abused drugs and information is readily available regarding the manufacture and distribution of these agents, interventions to reduce the abuse of prescription drugs have a greater potential for reducing overall drug abuse than efforts directed at the abuse of illegal drugs.

ALAN S. HOLLISTER
Division of Clinical Pharmacology,
University of Colorado Health
Sciences Center,
Denver, CO 80262

REFERENCES

1. "Project DAWN Annual Report, 1983" (National Institute on Drug Abuse, Rockville, MD, 1984); *Comprehensive Approach Needed to Help Control Prescription Drug Abuse*. Report by the Comptroller General to the Congress of the United States (Government

- Printing Office, Washington, DC, 1982).
2. *Retail Diversion of Legal Drugs—A Major Problem with No Easy Solution*. Report by the Comptroller General to the Congress of the United States (Government Printing Office, Washington, DC, 1978); G. R. Haislip, *Subst. Abuse* 4, 4 (1982).
3. Drug Enforcement Administration, Department of Justice, *Multiple Copy Prescription Programs Resource Guide* (Government Printing Office, Washington, DC, 1987).
4. A. S. Hollister, *Subst. Abuse* 11, 69 (1990).

Goldstein and Kalant provide an excellent review of the complex nature of forming a balanced policy on substance abuse both for an individual user and for the nation as a whole. There are, however, two areas that could have been clarified. The first relates to the use of operationally undefined terms such as "addiction" and "addictive drugs." The World Health Organization (WHO) (1) suggests that the term "neuroadaptation" be substituted for "dependence" and that the term "abuse" not be used because it is judgmental. WHO further recommends that "drug dependence syndrome" be used to encompass all of the phenomena previously described by the terms "dependence" and "abuse." The advantage of this new terminology is that it distinguishes between primary processes such as drug self-administration and the secondary consequences resulting from chronic drug intake (such as neuroadaptation). Finally, the terms proposed by WHO are more conducive to operational analyses and are devoid of value judgments, such as in the phrase "dangerous addicting drugs. . . ."

The above is not merely a semantic argument, as the choice of terminology leads to a second point. The data in Goldstein and Kalant's table 1 include a ranking system for the relative risk of addiction. There is no citation for this rank order or description of the methods used to determine these values. From the perspective of drug testing, pharmacologic assessments can be most effectively demarcated by the events before or after repeated drug-taking behavior (2). Such distinctions provide the foundation for separating drugs on the basis of their liability for abuse or their dependence potential, two properties that may or may not coexist (2). With respect to the former, there are a number of well-validated techniques for determining a drug's liability for abuse, both within and between pharmacologic classes (3). Similarly, a drug's dependence potential can be determined by using procedures that quantify the signs and symptoms that appear upon termination of chronic administration (2, 4). In fact, the original (and erroneous) idea that cocaine was a nonaddicting drug was based on early observations that it failed to produce marked physical dependence—in spite of its pronounced liability for abuse. Under the ominous term "addiction," the

origins of the rank orderings in Goldstein and Kalant's table 1 are unclear and may represent a mixture of scientific, social, and economic factors. However, once the latter two are included, the table no longer serves to predict risk, but rather conveys the element of consequence. It would have been more helpful had the authors included two columns: one that ranked the relative degrees of liability for abuse and dependence potential by using scientific criteria and the other showing measures of economic and social consequences.

SCOTT E. LUKAS
*Alcohol and Drug Abuse Research Center,
 McLean Hospital, Harvard Medical School,
 Belmont, MA 02178*

REFERENCES

1. World Health Organization, *Bull. WHO* 59, 225 (1981).
2. J. V. Brady and S. E. Lukas, Eds., *NIDA Research Monograph* 52 (ADM 84-1332, Department of Health and Human Services, Washington, DC, 1984).
3. R. R. Griffiths, L. D. Bradford, J. V. Brady, *Psychopharmacology* 65, 125 (1979); N. K. Mello, S. E. Lukas, M. P. Bree, J. H. Menderson, *Drug Alcohol Depend.* 21, 81 (1988); J. L. Katz, *Behav. Pharmacol.* 1, 283 (1990).
4. C. K. Himmelsbach, *J. Pharmacol. Exp. Ther.* 67, 239 (1939); H. F. Fraser and D. R. Jasinski, in *Drug Addiction I*, W. R. Martin, Ed. (Springer-Verlag, Berlin, 1977), pp. 589-612.

Goldstein and Kalant recognize the hypocrisy of the present differential prohibitions of psychoactive compounds. The authors are brave to call for decriminalizing the possession of small amounts of drugs, needle exchange programs, and treatments that begin by making the individual's drug of choice available. Unfortunately, the intensity of the "war on drugs" makes it difficult for even these authors to fairly estimate the hazards of revising the regulations for psychoactive compounds.

Goldstein and Kalant argue against drug legalization, fearing that the removal of explicit legal sanctions and subsequent increases in availability will lead to increased drug abuse. Data that are admittedly weakened by "the absence of sound national surveys" are cited to support the assertion that legalization would lead to an "increase in use [that] would be very large." However, the careful reader will find buried in reference 58 a more stringent evaluation; Goldstein and Kalant discredit similarly anecdotal reports that reducing penalties for possession of marijuana did not lead to substantially increased use of the drug in Holland or in many U.S. states. The authors note that "drug use has been declining . . . for all psychoactive drugs whether licit or illicit." Does not reduced consumption of cheap

and legal drugs such as caffeine and nicotine imply that a well-educated, free citizenry can make healthful decisions about drugs in the absence of punitive legal sanctions?

Goldstein and Kalant lament that a rational drug policy may be impractical since scientific evidence does not compete well with "long-established values and practices." The authors themselves prove this point, as their proposed changes in drug policy perpetuate a bias in favor of legal drugs and in opposition to illegal drugs. Implementing their suggestions would leave a vast discrepancy between the relative legal status and relative harm of drugs such as marijuana and alcohol. A society that holds freedom to be a basic value should be able to implement a drug policy based on science and should be able to develop means of discouraging drug abuse without recourse to hypocritical prohibitions.

ARTHUR P. LECCESE
*Department of Psychology,
 Kenyon College,
 Gambier, OH 43022-9623*

Response: Hollister is quite right in emphasizing the relatively much greater damage to health from licit substances, including prescription drugs, than from illicit ones. We agree completely, and did point this out in several places in our article. Moreover, we also cited the triple prescription program as a measure that had proven effective in reducing the abuse of benzodiazepines. We differ from Hollister only in the relative emphasis placed on different types of licit substance. Hollister cites statistics demonstrating that prescription drugs account for the great preponderance of emergency room visits and acute drug-related deaths. We have put more emphasis on the much greater total damage, including chronic illness and death, attributable to abuse of other licit substances, specifically alcohol and tobacco. The point on which we obviously agree is that it is essential to retain proper perspective in viewing the problems of drug abuse and to recognize that these are most definitely not confined to illicit "street" drugs.


Lukas' criticisms are well taken, and we must plead guilty to using terms that are not satisfactorily defined operationally. We were aware of this when we wrote our article. Indeed, one of us (H.K.) was a member of the World Health Organization working group (1) that proposed the term "neuroadaptation" and that rejected the term "drug abuse" because of its lack of definition and its obvious value-judgmental character. However, we chose to use the terms "addiction" and "drug abuse" for a practical and significant reason. The article was meant to be read, as we believe it has been, by people

Nanosphere™ Size Standards. Certified in billionths of a meter by Duke Scientific

Nanosphere Size Standards are calibrated in billionths of a meter (nanometers) and are available in 22 sizes from 21 to 900nm—all traceable to the National Bureau of Standards. Nanospheres are part of our complete line of spherical particles from 0.02 to 2000 micrometers in diameter. They are used as standards for instrument calibration, quality control, filter checking, and in numerous biotechnology applications. At Duke Scientific—established in 1971—we have the expertise and resources to meet any of your requirements for microspheres and particles. Call us today for information.




1135D San Antonio Road, Palo Alto, CA 94303, Toll Free
 (800) 334-3883, in CA (415) 962-1100, Fax (415) 962-0718



The ideal way to measure osmolality.

The biotechnology explosion has expanded the need for measuring the osmolality of solutions. Such measurements are critical in many areas of research. The most current and accurate means of measuring osmolality is the Wescor Vapor Pressure Osmometer. More than 5,500 laboratories now use the Wescor VPO routinely.



Here's why it's so popular:

- Accepts any biological sample, including viscous liquids, tissue specimens and cell suspensions with no need to alter the physical state of the specimen.
- Accepts sample volumes as small as 2 microliters.
- Avoids measurement artifacts that often accompany freezing point measurements.
- Electronic accuracy and reliability without mechanical complexity.

If you are working with living cells or have other applications for accurate concentration measurements, investigate the Wescor VPO. It's the ideal osmometer.

Contact Wescor, Inc. 459 South Main Street, Logan, UT 84321 USA. (801) 752-6011 or (800) 453-2725. FAX (801) 752-4127.

See us at FASEB Booth # 601-2

WESCOR®

Innovative instrumentation since 1970.

from a broad range of backgrounds, many of whom are not acquainted with the specific scientific concepts to which Lukas refers. We felt it better to write in terms that a general public knows and uses, so that attention would be directed to the major social policy issues surrounding the drug-related problems, rather than to the scientific analysis of the nature of dependence itself.

This is illustrated by our relative ranking of "risk of addiction" for different classes of drugs in our table 1. Lukas is correct in surmising that our rankings reflect "a mixture of scientific, social, and economic factors." Again, this was a deliberate choice. We acknowledge the scientific validity of Lukas' terminology; indeed, one of us (H.K.) was a contributor to the manual by Brady and Lukas (2) on scientific testing of drugs for their dependence potential and abuse liability. However, virtually every investigator in this field recognizes that the prevalence of problems attributable to any particular drug reflects not only the intrinsic pharmacological reinforcing effects of the drugs themselves, but also the influence of availability, fashion, social norms and current attitudes and beliefs. Our ranking was an (admittedly somewhat arbitrary) attempt to take these all into consideration. For example, if we had used only the results of test models such as those described by Brady and Lukas (2), we would not have included the hallucinogens at all, because they have proven to be aversive rather than reinforcing in animal models. Nevertheless, a few humans who use the drugs become sufficiently devoted to them to incur harmful consequences that justify inclusion of these drugs at the lowest level in our table.

Leccese appears to be suggesting that we supported our argument about the influence of easy availability on extent of drug use by referring to data that we ourselves recognized as faulty. This is not true. We noted the absence of sound national survey data about opiate use before the passage of the Harrison Act, but pointed out that Terry's work provided at least a valuable set of data for a circumscribed jurisdiction.

If Leccese's main contention is that "a well-educated, free citizenry can make healthful decisions about drugs in the absence of punitive legal sanctions," we agree with him completely. We stated, with respect to marijuana, "If preventive education achieves its goals, and public attitudes and other nonlegal controls over cannabis use become strong enough, it might eventually be possible to loosen the regulatory controls without risk of a major increase in use and the likely attendant problems." This would indeed be the ideal goal with respect to all drug use in a well-educated, free democratic

FOR YOUR CELL CULTURE NEEDS . . .

NOVO NORDISK

- TRANSFERRIN
- APROTININ
- TRYPSINS
- INSULINS


NOVO NORDISK BIOLABS PROVIDES THE HIGHEST QUALITY PRODUCTS TO SAVE YOU TIME AND MONEY. TWO OF NOVO NORDISK'S NEWEST SUPPLEMENTS FOR SERUM-FREE MEDIA ARE HUMAN TRANSFERRIN AND GENETICALLY ENGINEERED HUMAN INSULIN. THE INSULIN IS A FULL SEQUENCE PROTEIN PRODUCED IN *SACCHAROMYCES CEREVISIAE*.

IF YOUR RESEARCH DEMANDS THE BEST, NOVO NORDISK IS READY TO HELP WITH ALL YOUR CELL CULTURE NEEDS. OUR PRODUCTS ARE AVAILABLE IN INDIVIDUAL AND BULK QUANTITIES.

FOR MORE INFORMATION AND A FREE BROCHURE, CONTACT . . .

NOVO NORDISK A/S
NOVO ALLE
2880 BAGSVAERD
DENMARK
TEL +45 4444 8888
FAX +45 4298 9124

NOVO NORDISK BIOLABS
33 TURNER ROAD
P.O. BOX 1907
DANBURY, CT 06813-1907
TEL. 800 344-6686
TEL. 203 790-2770
FAX 203 790-2748



Prices valid until
August 31, 1991.

myo-INOSITOL 2-³H

Visit FASEB '91,
Booth 1455.

DEOXY GLUCOSE ¹⁴C, ³H

CAT. #	COMPOUND NAME	QTY.	DUPONT	AMERSHAM	*ARC
ARC-145	α-Aminoisobutyric acid [1- ¹⁴ C]	.25mCi	555	525	399
ARC-290	Arachidonic Acid [1- ¹⁴ C]	.05mCi	695	750	399
ART-196	Arachidonic Acid [³ H]	.25mCi	415	495	299
ARC-401	Chloramphenicol [¹⁴ C]	.05mCi	510	370	199
ART-146	Cytidine [³ H]	5mCi	—	—	539
ARC-114	Deoxy-2-fluoro glucose [¹⁴ C(U)]	.25mCi	—	1860	999
ARC-111	Deoxy-D-Glucose [1- ¹⁴ C]	1mCi	1200	1380	799
ART-103	Deoxy-D-Glucose [1,2- ³ H]	1mCi	325	—	199
ART-116 or	INOSITOL, myo [2- ³ H]-EtOH	1mCi	550	630	349
ART-116A	INOSITOL, myo [2- ³ H]-H ₂ O	5mCi	1395	1600	899
ARC-126	Iodoantipyrine [methyl ¹⁴ C]	1mCi	1375	1360	899
ARC-156	Leucine, L [1- ¹⁴ C]	.25mCi	890	850	599
ART-140	Leucine, L [4,5- ³ H]	5mCi	510	300	199
ART-126	3-O, Methyl ³ H D-Glucose	5mCi	525	—	299
ARC-452	Mevalonolactone, RS [2- ¹⁴ C]	.05mCi	260	235	199
ART-315	Mevalonolactone, RS [5- ³ H]	1mCi	460	—	299
ART-315	Mevalonolactone, RS [5- ³ H]	5mCi	1240	—	899
ART-318	Scopolamine methylchloride ³ H	1mCi	1000	1005	749
ART-314	Scopolamine [methyl ³ H]	1mCi	ARC	Exclusive	999
ARC-468	IPIA or IMP [methyl ¹⁴ C]	.25mCi	ARC	Exclusive	599

MEVALONOLACTONE ³H




AMERICAN RADIO LABELED CHEMICALS, INC.

11612 Bowling Green, St. Louis, MO 63146 USA

314-991-4545 FAX: 314-991-4692 TOLL FREE: 800-331-6661(US & CAN)

Circle No. 273 on Readers' Service Card

ELECTROPHORESIS ENGINEERING EXCELLENCE



Serva introduces a complete line of electrophoresis chambers and power supplies. Offered are the latest in vertical and mini-vertical slab chambers, submerged agarose gel units, semi-dry blotter, DNA-sequencer, IEF apparatus and power supplies up to 3500 volts. Innovative design and sturdy construction make these units user-friendly and durable.

SERVA

BIOCHEMICALS • SEPARATION TECHNOLOGY

50 A & S Drive • Paramus, New Jersey 07652

Phone: (201) 967-5900 and 800-645-3412

Telex #275658 Serv • Telefax # (201) 967-8858

Circle No. 246 on Readers' Service Card

society. But merely wishing it to be so does not automatically make it so. Our point is that it takes time and major effort to reach that desirable state of educated individual decision. In the interim, restrictive regulations can complement educational efforts in changing social consensus. In moving toward the ultimate goal, it is necessary to proceed cautiously and pragmatically, to avoid making things worse than they now are.

AVRAM GOLDSTEIN

Department of Pharmacology,

Stanford University School of Medicine,

Stanford, CA 94305

HAROLD KALANT

Department of Pharmacology,

University of Toronto,

Toronto, Ontario, Canada M5S 1A8

REFERENCES

1. World Health Organization, *Bull. WHO* 59, 225 (1981).
2. J. V. Brady and S. E. Lukas, Eds., *NIDA Research Monograph 52* (ADM 84-1332, Department of Health and Human Services, Washington, DC, 1984).

Alzheimer's Disease Cell Bank

The News briefing "Cell bank for mental illnesses" (11 Jan., p. 159) may have led some readers to mistakenly conclude that the National Institute of Mental Health's National Cell Repository is "the first nationally coordinated initiative to aid researchers in defining the genetic basis for Alzheimer's disease. . . ."

In fact, the National Institute on Aging-supported Alzheimer's Disease Research Center National Cell Bank has been in operation since September 1989 at Indiana University, in collaboration with Duke University. It is devoted to providing lymphoblast cultures from patients and family members with clinically diagnosed and pathologically confirmed Alzheimer's disease to investigators nationwide in an effort to speed the determination of the genetic defect that is associated with Alzheimer's disease.

ALLEN D. ROSES

Duke University Medical Center,

Durham, NC 27710

P. MICHAEL CONNEALLY

Department of Medical Genetics,

Indiana University,

Indianapolis, IN 46223

Erratum: The seventh sentence of the first paragraph of the letter from P. W. Anderson, E. Abrahams, and R. Laughlin that appeared in the issue of 1 March (pp. 1005-1006) was printed incorrectly. It should have read, "Others, such as the 'anyon' proponents, a group at Bell laboratories and Rutgers, and another at Princeton, are sure that this system is not a Fermi liquid."